Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application For BJ044 Injection
30/06/2026 02:33
BRIEF-Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application For BJ044 Injection June 30 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK:
NMPA APPROVES IND APPLICATION FOR BJ044 INJECTION, PERMITTING CLINICAL TRIALS
Further company coverage: 2659.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Bao Pharmaceuticals
See all newsBrief: Shanghai Bao Pharmaceuticals Says IND For BJ045 For Injection Was Approved By NMPA
Brief: Shanghai Bao Pharmaceuticals Co Announces U.S. FDA Approves Ind For Kj015 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves IND Application For BJ044 Injection
Brief: Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection